NASDAQ$IMMX

Immix Biopharma Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Headline financials

Total Revenue

$20M

No prior period
EPS (adj)

-$0.23

Previous: -$0.11-109.1%
Capital Expenditures

-$38.9K

No prior period
Free Cash Flow

-$4.32M

No prior period
Net Income

-$4.28M

Previous: -$1.54M-178.9%
Operating Income

-$4.52M

Previous: -$1.53M-195.0%
Gross Profit

$20M

No prior period
Cash & Equivalents

$19.6M

Previous: $16.9M+15.8%
Total Assets

$22.5M

Previous: $17.4M+29.2%
R&D Expense

$2.11M

No prior period
Stock-Based Comp

$737K

Previous: $163K+351.8%

Revenue & EPS history

Immix Biopharma · Revenue · Quarterly

$20M

Q3 2023

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-2.1%

Avg return

Earnings day

+1.2%

Avg return

5 days after

+13.0%

Avg return

30 days after

24%

5 / 21 earnings

Positive

+11.3%

Q2 2021

Best reaction

-11.3%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-7.8%+3.0%-23.4%
Q4 2025+4.2%+0.1%+14.9%
Q3 2025+2.5%+14.6%+95.2%
Q4 2024+0.0%-2.2%-4.3%
Q2 2025-2.6%-8.4%-9.2%
Q1 2025-1.0%-6.6%+11.8%
Q3 2024-11.3%-10.2%+20.3%
Q2 2024-4.6%-2.6%-4.6%
Q1 2024-2.7%-1.8%-9.4%
Q4 2023-4.9%-0.3%-30.6%
Q3 2023+5.0%+4.1%-0.5%
Q2 2023-3.7%-6.8%+37.4%
Q1 2023-5.9%-19.2%-9.1%
Q4 2022-2.2%-0.5%+1.1%
Q3 2021-8.6%+25.6%+69.5%
Q3 2022-8.6%+25.6%+69.5%
Q2 2022-4.9%-7.7%-26.8%
Q1 2021-5.0%-7.1%+73.6%
Q1 2022-5.0%-7.1%+73.6%
Q4 2021+11.3%+16.4%-37.6%
Q2 2021+11.3%+16.4%-37.6%
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro